Porshia Turner
Family · Greenville, SCNPI 1265001531
Payments from drug & device makers
Across 360 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Amgen$727
- TG Therapeutics, Inc.$618
- AbbVie$493
- Novartis$362
- plus $3K from 31 others
Across 16 payments — averaging $160.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$3K
What the payments were for
- Consulting fees$3004%
- Food & beverage$7,62896%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 48 | $1,286 |
| Teva Pharmaceuticals USA, Inc. | 120 | $1,210 |
| Amgen(2 entities) | 17 | $727 |
| TG Therapeutics, Inc. | 18 | $618 |
| AbbVie | 26 | $493 |
| Novartis | 17 | $362 |
| Biogen | 4 | $350 |
| Bristol Myers Squibb | 19 | $307 |
| Biohaven Pharmaceuticals, Inc. | 6 | $285 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $211 |
| E.r. Squibb & Sons, L.L.C. | 2 | $203 |
| Pfizer | 7 | $200 |
| Argenx US, Inc. | 6 | $196 |
| Acadia Pharmaceuticals Inc | 10 | $168 |
| AstraZeneca | 7 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $152 |
| Eisai Inc. | 5 | $117 |
| Lilly USA, LLC | 6 | $115 |
| Neurocrine Biosciences, Inc. | 4 | $87 |
| Impel Pharmaceuticals LLC | 3 | $80 |
| Vanda Pharmaceuticals Inc. | 3 | $74 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| Axsome Therapeutics, Inc. | 3 | $72 |
| Genentech USA, Inc. | 3 | $56 |
| Banner Life Sciences, LLC | 2 | $54 |
| UCB, Inc. | 1 | $41 |
| Tonix Medicines, Inc. | 1 | $41 |
| ANI Pharmaceuticals, Inc. | 1 | $35 |
| Amneal Pharmaceuticals LLC | 1 | $29 |
| Hospira, Inc. | 1 | $27 |
| Merz Pharmaceuticals, LLC | 1 | $25 |
| Sanofi | 1 | $25 |
| Acorda Therapeutics, Inc | 1 | $24 |
| Upsher-smith Laboratories LLC | 1 | $23 |
| Harmony Biosciences LLC | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYSABRI$300
- Mavenclad$253
- UPLIZNA$252
- NURTEC ODT$250
- BRIUMVI$134
- ZEPOSIA$122
- Austedo XR$105
How this compares
$7,970 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RebifInterferon Beta-1a/Albumin | 15 | $152,069 |
| IngrezzaValbenazine Tosylate | 12 | $93,865 |
| CopaxoneGlatiramer Acetate | 11 | $64,361 |
| UbrelvyUbrogepant | 27 | $30,109 |
| Nurtec OdtRimegepant Sulfate | 20 | $25,337 |
| QuliptaAtogepant | 14 | $20,157 |
| BotoxOnabotulinumtoxina | 12 | $16,504 |
| Dalfampridine ErDalfampridine | 37 | $12,222 |
| Dimethyl Fumarate | 19 | $5,273 |
| FingolimodFingolimod Hcl | 12 | $2,557 |
| Modafinil | 18 | $1,988 |
| Carbamazepine ErCarbamazepine | 13 | $1,954 |
| Baclofen | 97 | $1,267 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 21 | $1,203 |
| Tolterodine Tartrate ErTolterodine Tartrate | 13 | $997 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Rebif | $1,286 | $152,06915 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $87 | $93,86512 claims |
| AbbVieUbrelvy, Qulipta, Botox | $493 | $66,77053 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $1,210 | $64,36111 claims |
| PfizerNurtec Odt | $200 | $25,33720 claims |
| Upsher-smith Laboratories LLCTopiramate | $23 | $51016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.
Other family in Greenville
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Carrie HendersonGreenville$91K
- Michelle StrongGreenville$55K
- Melissa BrownlowGreenville$20K
- Sarah McNightGreenville$15K
- Melissa MotesGreenville$13K
- Matthew KeatonGreenville$10K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.